As of July 6, according to a recent Reuters survey, 28 analysts are tracking TEVA stock. Six of them have given it a “buy” or “strong buy” recommendation, and 15 of them have given it a “hold.” Seven analysts have rated the stock a “sell.”
As of July 6, the analysts’ consensus target price for TEVA stock for the next 12 months is $20.13. That represents a return of -15.8% on an investment in TEVA stock for the next 12 months. The return is based on TEVA’s closing price of $23.92 on July 5.
Analysts’ average target prices for Teva’s peers Pfizer (PFE), Mylan (MYL), and Eli Lilly (LLY) are $39.86, $48.63, and $91.26, respectively. That implies returns of 8.1%, 34%, and 5.4%, respectively, over the next 12 months.
Recent ratings and target price updates
On July 3, Bernstein raised its target price on TEVA stock from $20 to $26. On June 11, Leerink Partners raised its target price from $13 to $16. In May, Citigroup and Barclays also raised their target prices on Teva.
In the next part of this series, we’ll look at Teva’s recent stock performance.